Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a/1b EMBER study
伊姆鲁司群（一种口服选择性雌激素受体降解剂）联合HER2靶向治疗，无论是否联合阿贝西利，用于治疗ER阳性、HER2阳性晚期乳腺癌：来自EMBER 1a/1b期研究的结果
期刊:Breast Cancer Research
影响因子:5.6
doi:10.1186/s13058-025-02168-6
Bhave, Manali; Jhaveri, Komal L; Kaufman, Peter A; Aftimos, Philippe; Lombard, Janine; Giridhar, Karthik V; Im, Seock-Ah; Ma, Cynthia X; Lee, Kuo-Ting; Kim, Sung-Bae; Sohn, Joohyuk; Li, Yujia; Yuen, Eunice; Estrem, Shawn T; Nguyen, Bastien; Makena, Monish Ram; Ismail-Khan, Roohi; Beeram, Muralidhar
